Cílená terapie u kostních sarkomů
| Authors | |
|---|---|
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Onkológia |
| MU Faculty or unit | |
| Citation | |
| Keywords | bone sarcoma, targeted therapy, angiogenesis, proteinkinase inhibitor |
| Description | Therapy success in bone sarcoma is significantly better compared to history cohorts with 60-70 % overall survival to date. Unfortunately, there is yet not shift and movement in better survival of patients with relapsed and refractory bone sarcomas during last twenty years. This article reviews targeted therapeutics in bone sarcomas which are undr investigation and which could give chance to patients suffering from relapsed and chemoresistant bone sarcomas. Majority of the targeted drugs are given as part of phase 1 or 2 studies. |